A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma

References

• Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol 1953; 26:234–41; PMID:13042090; https://doi.org/10.1259/0007-1285-26-305-234
   PubMed Web of Science ®Google Scholar
• Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): A curative approach? Nat Rev Clin Oncol 2016; 13:516–24; PMID:26951040; https://doi.org/10.1038/nrclinonc.2016.30
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 2012; 84:879–80; PMID:23078897; https://doi.org/10.1016/j.ijrobp.2012.06.020
   PubMed Web of Science ®Google Scholar
• Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012; 83:1306–10; PMID:22208977; https://doi.org/10.1016/j.ijrobp.2011.09.049
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst 2013; 105:256–65; PMID:23291374; https://doi.org/10.1093/jnci/djs629
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252–64; PMID:22437870; https://doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925–31; PMID:22397654; https://doi.org/10.1056/NEJMoa1112824
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM, Knox SJ. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 2012; 5:404–7; PMID:23323154; https://doi.org/10.1593/tlo.12280
   PubMed Web of Science ®Google Scholar
• Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013; 2:899–906; PMID:24403263; https://doi.org/10.1002/cam4.140
   PubMed Web of Science ®Google Scholar
• Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2013; 85:293–5; PMID:22560555; https://doi.org/10.1016/j.ijrobp.2012.03.017
   PubMed Web of Science ®Google Scholar
• Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013; 1:365–72; PMID:24563870; https://doi.org/10.1158/2326-6066.CIR-13-0115
   PubMed Web of Science ®Google Scholar
• Bedke J, Gauler T, Grunwald V, Hegele A, Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, Zastrow S, Miller K. Systemic therapy in metastatic renal cell carcinoma. World J Urol 2017; 35:179-88; PMID:27277600; https://doi.org/10.1007/s00345-016-1868-5
   PubMed Web of Science ®Google Scholar
• Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011; 16(Suppl 2):4–13; PMID:21346035; https://doi.org/10.1634/theoncologist.2011-S2-04
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl 3):i49–56; PMID:25210086; https://doi.org/10.1093/annonc/mdu259
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373:1803–13; PMID:26406148; https://doi.org/10.1056/NEJMoa1510665
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14:985–90; PMID:18670422; https://doi.org/10.1038/nm.1789
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368:1199–209; PMID:23484797; https://doi.org/10.1056/NEJMoa1213261
   PubMed Web of Science ®Google Scholar
• Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497:108–12; PMID:23563269; https://doi.org/10.1038/nature12065
   PubMed Web of Science ®Google Scholar
• Yong E. Cancer biomarkers: Written in blood. Nature 2014; 511:524–6; PMID:25079538; https://doi.org/10.1038/511524a
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 2015; 33:1430–7; PMID:25452452; https://doi.org/10.1200/JCO.2014.59.0703
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu L, Yu D, Kandimalla ER, Sun HB, Agrawal S, Guha C. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PLoS One 2012; 7:e38111; PMID:22666458; https://doi.org/10.1371/journal.pone.0038111
   PubMed Web of Science ®Google Scholar
• Gerber NK, Young RJ, Barker CA, Wolchok JD, Chan TA, Yamada Y, Friguglietti L, Beal K. Ipilimumab and whole brain radiation therapy for melanoma brain metastases. J Neurooncol 2015; 121:159–65; PMID:25273687; https://doi.org/10.1007/s11060-014-1617-9
   PubMed Web of Science ®Google Scholar
• Low TL, Thurman GB, McAdoo M, McClure J, Rossio JL, Naylor PH, Goldstein AL. The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus. J Biol Chem 1979; 254:981–6; PMID:216684
   PubMed Web of Science ®Google Scholar
• Goldstein AL. History of the discovery of the thymosins. Ann N Y Acad Sci 2007; 1112:1–13; PMID:17600284; https://doi.org/10.1196/annals.1415.045
   PubMed Web of Science ®Google Scholar
• Pierluigi B, D'Angelo C, Fallarino F, Moretti S, Zelante T, Bozza S, De Luca A, Bistoni F, Garaci E, Romani L. Thymosin alpha1: The regulator of regulators? Ann N Y Acad Sci 2010; 1194:1–5; PMID:20536444; https://doi.org/10.1111/j.1749-6632.2010.05465.x
   PubMed Web of Science ®Google Scholar
• Garaci E, Pica F, Matteucci C, Gaziano R, D'Agostini C, Miele MT, Camerini R, Palamara AT, Favalli C, Mastino A, et al. Historical review on thymosin alpha1 in oncology: Preclinical and clinical experiences. Expert Opin Biol Ther 2015; 15(Suppl 1):S31–9; PMID:26096345; https://doi.org/10.1517/14712598.2015.1017466
   PubMed Web of Science ®Google Scholar
• Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 2010; 28:1780–7; PMID:20194853; https://doi.org/10.1200/JCO.2009.25.5208
   PubMed Web of Science ®Google Scholar